For more updates follow Grant Thornton Bharat on WhatsApp
India’s pharma and healthcare sector remained active in Q3 2026 as organisations advanced consolidation, regional expansion and capability-building agendas. Transactions reflected a focus on strengthening networks, enhancing specialised capabilities and aligning portfolios with strategic priorities. The Q3 2026 edition of the Pharma and Healthcare Dealtracker analyses the key themes, investment priorities and transaction drivers shaping sector activity during the quarter. Activity across healthcare delivery, diagnostics, manufacturing, health technology and wellness highlighted sustained interest in scale, reach and platform-led growth.
Q3 2026 marks the highest quarterly volumes ever with 87 deals valued at USD 4.3 billion, up 34% QoQ and 23% YoY. The lower value versus Q2 2026 was largely due to the USD 11.8 billion Sun Pharma–Organon deal rather than a slowdown. Deal activity broadened during the quarter, while values remained concentrated in a few large transactions.
M&A volumes rose 6% QoQ to 37 deals valued USD 500 million, with domestic transactions accounting for 73% of the deals. The average ticket size fell to USD 13.5 million from about USD 42 million in Q2 2026, excluding the Sun Pharma–Organon deal, reflecting consolidation through smaller, capability-led acquisitions.
PE/VA activity strengthened meaningfully, with 44 investments worth USD 2.3 billion, representing the second-highest PE/VC deal volume since Q2 2022 and the strongest quarter by value since Q3 2024. Value growth was driven by one deal valued at over USD 1 billion and two deals valued above USD 100 million. The top five deals alone accounted for 88% of the value.
The strongest IPO value quarter in the series with 4 issues raising USD 1.3 billion, exceeding the combined proceeds of USD 76 million raised during H1 2026. However, Manipal Health Enterprises accounted for 77% of IPO proceeds, indicating improved access for scaled issuers rather than a broad reopening. Fundraising via the QIP route remains similar to Q2 with 2 deals worth USD 162 million.
In Q2 2026, pharma and healthcare deal activity reflected a selective investment environment. Strategic acquisitions, portfolio strengthening and capability-led expansion remained key themes across the sector.
Delhi has built one of India’s most advanced healthcare ecosystems, serving over two crore residents and acting as a leading referral hub for tertiary and quaternary care across North India.
Healthcare worker safety in India has emerged as one of the most pressing challenges facing the country's healthcare system.
